ACT adds SMD clinical trial site

Mon, 08/20/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

Advanced Cell Technology Inc. of Marlborough has added a third site for its clinical trial for Stargardt’s Macular Dystrophy, a genetic disorder that affects up to 100,000 patients in the U.S. and Europe and can sometimes lead to blindness in children between the ages of 10 and 20. NHS Lothian, a hospital in Scotland that provides primary, community-based and acute hospital services for approximately 800,000 people, was selected as the third site to host the trial of SMD, an incurable disease according to ACT Chief Scientific Officer Robert Lanza.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.